Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center, Addis Ababa, Ethiopia.
PLoS One. 2020 Dec 30;15(12):e0244269. doi: 10.1371/journal.pone.0244269. eCollection 2020.
Various factors may determine the duration of viral shedding (the time from infection to viral RNA-negative conversion or recovery) in COVID-19 patients. Understanding the average duration of recovery and its predictors is crucial in formulating preventive measures and optimizing treatment options. Therefore, evidence showing the duration of recovery from COVID-19 in different contexts and settings is necessary for tailoring appropriate treatment and prevention measures. This study aimed to investigate the average duration and the predictors of recovery from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection among COVID-19 patients.
A hospital-based prospective cohort study was conducted at Eka Kotebe General Hospital, COVID-19 Isolation and Treatment Center from March 18 to June 27, 2020. The Center was the first hospital designated to manage COVID-19 cases in Ethiopia. The study participants were all COVID-19 adult patients who were admitted to the center during the study period. Follow up was done for the participants from the first date of diagnosis to the date of recovery (negative Real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCT) test of throat swab).
A total of 306 COVID-19 cases were followed up to observe the duration of viral clearance by rRT-PCR. Participants' mean age was 34 years (18-84 years) and 69% were male. The median duration of viral clearance from each participant's body was 19 days, but the range was wide: 2 to 71 days. Cough followed by headache was the leading sign of illness among the 67 symptomatic COVID-19 patients; and nearly half of those with comorbidities were known cancer and HIV/AIDS patients on clinical follow up. The median duration of recovery from COVID-19 was different for those with and without previous medical conditions or comorbidities. The rate of recovery from SARS-CoV-2 infection was 36% higher in males than in females (p = 0.043, CI: 1.01, 1.85). The rate of recovery was 93% higher in those with at least one comorbidity than in those without any comorbidity. The risk of delayed recovery was not influenced by blood type, BMI and presence of signs or symptoms. The findings showed that study participants without comorbidities recovered more quickly than those with at least one comorbidity. Therefore, isolation and treatment centers should be prepared to manage the delayed stay of patients having comorbidity.
多种因素可能决定 COVID-19 患者的病毒脱落持续时间(从感染到病毒 RNA 阴性转换或康复的时间)。了解平均康复时间及其预测因素对于制定预防措施和优化治疗方案至关重要。因此,需要了解不同背景和环境下 COVID-19 患者康复时间的证据,以便制定适当的治疗和预防措施。本研究旨在调查 COVID-19 患者中严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的平均康复时间及其预测因素。
这是一项在 2020 年 3 月 18 日至 6 月 27 日期间在埃塞俄比亚埃卡科特贝综合医院 COVID-19 隔离治疗中心进行的基于医院的前瞻性队列研究。该中心是埃塞俄比亚第一家管理 COVID-19 病例的医院。研究参与者均为在研究期间入住该中心的 COVID-19 成年患者。对参与者进行随访,从诊断的第一天到康复(咽拭子实时逆转录聚合酶链反应(rRT-PCR)检测为阴性)的日期。
共有 306 例 COVID-19 病例接受了 rRT-PCR 病毒清除持续时间的随访。参与者的平均年龄为 34 岁(18-84 岁),69%为男性。每位参与者的病毒清除中位时间为 19 天,但范围很广:2-71 天。在 67 例有症状的 COVID-19 患者中,以咳嗽伴头痛为主要症状;在有合并症的患者中,近一半是已知的癌症和 HIV/AIDS 患者,正在接受临床随访。有和没有既往病史或合并症的 COVID-19 患者的康复中位时间不同。与女性相比,男性的 SARS-CoV-2 感染康复率高 36%(p=0.043,CI:1.01,1.85)。至少有一种合并症的患者的康复率比没有任何合并症的患者高 93%。康复率不受血型、BMI 和体征或症状的影响。研究结果表明,无合并症的研究参与者比至少有一种合并症的患者康复得更快。因此,隔离和治疗中心应做好准备,以管理有合并症的患者的延迟逗留。